Sugar coating may be key to rare disease diagnosis

NCT ID NCT07448779

Recruiting now Knowledge-focused Sponsor: Fondazione IRCCS Policlinico San Matteo di Pavia Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study investigates how a sugar modification called N-glycosylation affects AL amyloidosis, a rare disease where abnormal proteins build up in organs. Researchers will analyze blood and bone marrow samples from 100 adults with related conditions to better understand the disease and improve diagnosis. The goal is to gather knowledge, not to test a new treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could lead to better risk assessment and diagnostic tools for AL amyloidosis, and potentially identify new treatment targets.
What could go wrong: This is an observational study, not a treatment trial. It is early-stage research, and findings may not directly translate into new therapies or clinical changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AL AMYLOIDOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

AL amyloidosis Immunoglobulin Light-chain Amyloidosis monoclonal gammopathy monoclonal gammopathy of uncertain significance plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AL AMYLOIDOSIS MGUS MONOCLONAL GAMMOPATHIES MULTIPLE MYELOMA

Contacts and locations

Locations

Fondazione IRCCS Policlinico San Matteo di Pavia
RECRUITING

Pavia, PV, 27100, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.